Eli Lilly shares surge toward new highs as obesity drug data and earnings momentum reshape Wall Street expectations

Eli Lilly’s stock has begun behaving less like a beaten-down drugmaker and more like a market leader again, according to a new price-target discussion from 24/7 Wall St. The article argues that after a difficult period late last year and an uneven start to 2026, LLY shares recently pushed through new 52-week highs, helped by continued investor focus on retatrutide, the company’s investigational obesity medicine. In the post’s framing, the market is re-interpreting Lilly’s growth prospects as the obesity pipeline moves through late-stage testing.

The 24/7 Wall St. piece points to valuation and recent price action as the setup for its forecast. It states that LLY was trading around $1,149.15 and that the stock’s one-year gain was about 50.31%, while year-to-date performance was closer to 7.29%. The post also notes that shares rose about 21.37% over the prior month and about 6.19% over the prior week, suggesting momentum returned after a period when investors had been cautious.

Underlying the forecast is the market’s focus on retatrutide Phase 3. The article describes Wall Street analysts viewing the Phase 3 results as potentially first-line for obesity, and it contrasts retatrutide’s weight-loss profile with competitive efforts. It cites AstraZeneca’s elecoglipron as entering Phase 3, and it characterizes the competitive data by saying elecoglipron showed about 11.8% weight loss versus retatrutide’s roughly 19%. While the post does not provide complete trial details, it suggests that investors are beginning to price in a stronger relative positioning for Lilly’s obesity program.

The article also ties the stock’s strength to earnings performance and several earlier headwinds. It says investors had worried in the first quarter about China NRDL pricing pressure, as well as $584 million in in-process research and development charges tied to four acquisitions and the impact of 340B restrictions. It further claims that earlier volatility was more about earnings noise than broad market turbulence, pointing to a low “beta” of 0.517 in the post’s analysis.

In its scenario work, 24/7 Wall St. presents a consensus analyst target and its own expectations. The post states that the consensus target was $1,215.10, describing the distribution of analyst ratings as heavily bullish. It also provides three cases: a base case around $1,295.73, an optimistic case around $1,499.61, and a conservative case around $1,074.25, each with differing confidence levels. The post emphasizes that moving from $1,149.15 to $1,500 would require about a 30.5% gain.

The piece further adds a valuation pathway. It says forward earnings per share (EPS) were cited at $35.46 and that a $1,500 share price would imply a forward price-to-earnings multiple of roughly 42x. In its base-case valuation framing, it implies that the required jump would be accomplished with continued earnings growth and more modest additional multiple expansion rather than relying solely on a dramatic improvement in fundamentals.

Separately, other market-oriented analysis referenced in the research context also supports the general theme that Lilly’s growth trajectory and obesity market potential are driving long-range valuation discussions. Trefis, for example, lays out a longer-term path in which Lilly’s revenue expands and its valuation multiples remain elevated, arguing that the company’s scaling and earnings growth can support much higher share prices over time. That said, those forecasts are not Lilly’s own guidance, and the 24/7 Wall St. post itself remains a model-based prediction rather than a company-issued outlook.

For readers, the main uncertainty remains what Lilly will disclose next and how competitive and regulatory developments evolve. The 24/7 Wall St. post does not lay out full Phase 3 endpoints or timelines, and it does not quantify trial subgroup results, safety findings, or manufacturing and reimbursement details. It also does not specify whether any additional obesity competitors will report mature Phase 3 outcomes on a similar schedule. What to watch next is likely to include further clinical updates on retatrutide, any company commentary on pricing and access (including outside the U.S.), and additional quarterly results that confirm whether earnings strength can sustain the current valuation narrative.